OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference

Rhea-AI Summary

OS Therapies (NYSE American: OSTX) has announced its participation in the H.C. Wainright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024, in New York City. The company's President & CEO, Paul Romness, MPH, will deliver a virtual presentation highlighting:

• The company's potentially pivotal fully-enrolled Phase 2b trial of OST-HER2 for preventing resected, recurrent human osteosarcoma
• OST-HER2's pending pivotal safety study in treating canine osteosarcoma
• The company's tunable Antibody Drug Conjugate (tADC) therapeutic platform technology

The virtual presentation will be available starting at 7:00 AM ET on September 9, 2024. Interested parties can register for the conference at https://hcwevents.com/annualconference/.

NEW YORK--(BUSINESS WIRE)-- OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced its participation in the H.C. Wainright 26^th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York City. The Company’s President & CEO Paul Romness, MPH, will deliver a virtual presentation highlighting the Company’s potentially pivotal fully-enrolled Phase 2b trial of its off-the-shelf immunotherapy candidate OST-HER2 in the prevention of resected, recurrent human osteosarcoma, OST-HER2’s pending pivotal safety study in the treatment of canine osteosarcoma and the Company’s tunable Antibody Drug Conjugate (tADC) therapeutic platform technology.

Presentation Details:

Event:	H.C. Wainwright 26th Annual Global Investment Conference
Date:	September 9-11, 2024
Virtual Presentation:	Available starting at 7:00 AM, ET, September 9, 2024
Registration:	https://hcwevents.com/annualconference/

About OS Therapies

OS Therapies is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma, with results expected in the fourth quarter of 2024. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing strong preclinical efficacy data in various models of breast cancer. In addition, OS Therapies is advancing its next generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company’s proprietary silicone linker technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those described under the section entitled “Risk Factors” of our Registration Statement on Form S-1 declared effective by the Securities and Exchange Commission (the “SEC”) on July 31, 2024, as well as any of our periodic reports filed with the SEC, and that actual results may differ materially from those indicated by such forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240905021496/en/

Corporate and Media Contact:

Jack Doll

410-297-7793

Irpr@ostherapies.com

Investor Relations:

Dave Gentry

RedChip Companies, Inc.

1-407-644-4256

OSTX@redchip.com

Source: OS Therapies

FAQ

When is OS Therapies (OSTX) presenting at the H.C. Wainright Global Investment Conference?

OS Therapies (OSTX) will present virtually at the H.C. Wainright 26th Annual Global Investment Conference, with the presentation available starting at 7:00 AM ET on September 9, 2024.

What will OS Therapies (OSTX) discuss in their presentation at the H.C. Wainright conference?

OS Therapies (OSTX) will highlight their Phase 2b trial of OST-HER2 for human osteosarcoma, OST-HER2's safety study for canine osteosarcoma, and their tunable Antibody Drug Conjugate (tADC) therapeutic platform technology.

How can investors access OS Therapies' (OSTX) presentation at the H.C. Wainright conference?

Investors can access OS Therapies' (OSTX) virtual presentation by registering for the H.C. Wainright 26th Annual Global Investment Conference at https://hcwevents.com/annualconference/.

What is the current status of OS Therapies' (OSTX) Phase 2b trial for OST-HER2?

OS Therapies' (OSTX) Phase 2b trial of OST-HER2 for preventing resected, recurrent human osteosarcoma is described as potentially pivotal and fully-enrolled.